MabTics
Seoul, South Korea· Est.
Innovative antibody platform focused on vessel normalization for oncology, vascular, and eye diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $1.6M
AI Company Overview
Innovative antibody platform focused on vessel normalization for oncology, vascular, and eye diseases.
OncologyVascular DiseaseOphthalmologyImmunology
Technology Platform
EAGLES high‑diverse antibody library for rapid generation of functional antibodies, combined with Tie2‑activating antibodies that normalize abnormal vasculature.
Opportunities
MabTics can leverage its vessel‑normalization platform to enter high‑need oncology and ophthalmology markets, and its early partnerships provide pathways to rapid clinical development and out‑licensing.
Risk Factors
Scientific uncertainty of novel Tie2‑activating antibodies, pre‑clinical stage without revenue, and competition from established anti‑angiogenic and Tie2‑targeting programs.
Competitive Landscape
Key competitors include companies developing Angiopoietin‑1 mimetics (e.g., AKB‑9778) and other vessel‑normalization approaches; MabTics differentiates through its EAGLES library and dual focus on mono‑ and bispecific formats.